Oncopeptides
2.13 SEK -10.13%1 investor is following this company
Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ONCO
Daily low / high price
1.998 / 2.54
SEK
Market cap
458.35M SEK
Turnover
9.13M SEK
Volume
4.2M
Latest videos
Financial calendar
Interim report
14.08.2024
Interim report
07.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
HealthCap VIII L.P. | 12.7 % | 12.9 % |
Avanza Pension | 7.9 % | 8.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Oncopeptides publishes Q2 report 2024
Invitation to presentation of the Q2 report 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools